About Kamal Therapeutics
Kamal Therapeutics is a private company based in Hingham, Massachusetts, incorporated in 2020 in Delaware. It has reported $23,750,138 raised in two offerings on Form D since August 2021. Its chief executive is Mark de Souza.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2025 | Nov 24, 2025 | $13,807,138of $17.3M target | 41 | $336K | EquityRule 506(b) | Form D ↗ |
| Aug 18, 2021 | Aug 27, 2021amended Oct 11, 2022 | $9,943,000of $10.0M target | 37 | $268K | Debt, OptionsRule 506(b) | Form D/A ↗1 earlier filing |
| Total, two offerings | $23,750,138 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Kamal Therapeutics's Form D filed Nov 24, 2025.
MS
Mark de Souza
President and Chief Executive Officer, director
PR
Philip Reilly
Director
JP
John Parker
Director
Earlier filings also listed Joff Masukawa (director, last listed Oct 2022), Hal Landy (director, last listed Oct 2022), Deborah Ramsdell (president and chief executive officer, director, last listed Oct 2022) and Alexander Silver (director, last listed Oct 2022).